These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19748901)

  • 1. Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma.
    Trojan A; Montemurro M; Kamel M; Kristiansen G
    Ann Oncol; 2009 Nov; 20(11):1898-9. PubMed ID: 19748901
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
    J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
    Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIT and PDGF as targets.
    Verweij J
    Cancer Treat Res; 2004; 120():117-27. PubMed ID: 15217221
    [No Abstract]   [Full Text] [Related]  

  • 6. Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.
    Srinivas U; Barwad A; Pubbaraju SV
    Br J Haematol; 2014 Jun; 165(5):583. PubMed ID: 24456122
    [No Abstract]   [Full Text] [Related]  

  • 7. [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
    Helbig G; Stella-Hołowiecka B; Hołowiecki J
    Pol Arch Med Wewn; 2005 May; 113(5):490-7. PubMed ID: 16479834
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
    Heinrich MC; Corless CL
    Cancer Treat Res; 2004; 120():129-50. PubMed ID: 15217222
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
    Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
    Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
    [No Abstract]   [Full Text] [Related]  

  • 10. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha.
    Candelaria M; Arias-Bonfill D; Chávez-Blanco A; Chanona J; Cantú D; Pérez C; Dueñas-González A
    Int J Gynecol Cancer; 2009 Dec; 19(9):1632-7. PubMed ID: 19955950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.
    Metzgeroth G; Schwaab J; Gosenca D; Fabarius A; Haferlach C; Hochhaus A; Cross NC; Hofmann WK; Reiter A
    Leukemia; 2013 Nov; 27(11):2254-6. PubMed ID: 23615556
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of STI-571, a c-kit tyrosine kinase inhibitor, in mestastasic gastrointestinal tumor].
    Calvo E; Fernández FJ; Forteza J; Brugarolas A
    Med Clin (Barc); 2002 Sep; 119(10):396-7. PubMed ID: 12372175
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
    De Pas T; Toffalorio F; Colombo P; Trifirò G; Pelosi G; Vigna PD; Manzotti M; Agostini M; de Braud F
    J Thorac Oncol; 2008 Aug; 3(8):938-41. PubMed ID: 18670317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of mast cell sarcoma of the uterus with imatinib.
    Ma HB; Xu X; Liu WP; Chang H; Zeng F; Wang YC
    Int J Hematol; 2011 Nov; 94(5):491-4. PubMed ID: 22020400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571).
    Holcombe RF; Gu M; Imagawa D; Milovanovic T
    Anticancer Drugs; 2003 Sep; 14(8):651-7. PubMed ID: 14501388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I; Blay JY
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.